Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma

Manali Dimri * and Ande Satyanarayana

Department of Biochemistry and Molecular Biology, Molecular Oncology & Biomarkers Program, Georgia Cancer Center, Augusta University, Room-CN3144, 1410 Laney Walker Blvd., Augusta, GA 30912, USA; sande@augusta.edu
* Correspondence: mdimri@augusta.edu; Tel.: +1-706-306-7675

Received: 17 December 2019; Accepted: 18 February 2020; Published: 20 February 2020

Abstract: Hepatocellular carcinoma (HCC) is a complex biological process and is often diagnosed at advanced stages with no effective treatment options. With advances in tumor biology and molecular genetic profiling, several different signaling pathways and molecular mechanisms have been identified as responsible for initiating and promoting HCC. Targeting these critical pathways, which include the receptor tyrosine kinase pathways, the Ras mitogen-activated protein kinase (Ras/Raf/MAPK), the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), the Wnt/β-catenin signaling pathway, the ubiquitin/proteasome degradation and the hedgehog signaling pathway has led to the identification of novel therapeutics for HCC treatment. In this review, we elaborated on our current understanding of the signaling pathways involved in the development and initiation of HCC and anticipate the potential targets for therapeutic drug development.

Keywords: Hepatocellular carcinoma; signaling pathway; targeted therapy

1. Introduction

Hepatocellular carcinoma (HCC) accounts for 7% of all the cancers worldwide, and is the most common primary liver malignancy [1]. It is an aggressive tumor with a poor prognosis and is the second leading cause of cancer-related mortality. Over the past two decades, the incidence of HCC has doubled in the United States, Europe and many other countries. With 800,000 cases being diagnosed and an estimated 750,000 causalities annually worldwide [2]. The most common risk factors associated with the development of HCC include chronic hepatitis B and C virus infection. Approximately 75% of HCCs are associated with hepatitis infection, which might lead to a twenty-fold increase in HCC development [3]. Other major risk factors include chronic alcohol consumption, obesity, aflatoxin B1 (AFB1) exposure and nonalcoholic fatty liver disease (NAFLD) [4].

Current treatment options, including liver transplantation or surgical resections, can cure patients at early stages of HCC [5,6]. However, advanced HCC is diagnosed in 80% of patients, mainly due to a lack of symptoms and effective screening strategies for HCC [7]. Due to limited treatment options, systemic drug doses are often used, particularly when surgical sectioning is not possible. Unfortunately, HCC is also highly resistant to conventional chemotherapies with cytotoxic agents. Overall, the current treatment strategy for HCC can offer survival benefit, particularly to patients in early stages [8]. Only 30–40% of all the HCC patients are diagnosed as eligible for current treatment options due to late diagnosis [9,10].

HCC is a complex multistep biological process that involves genetic and epigenetic alterations [11]. There has been tremendous progress in our understanding of the critical oncogenic and tumor suppressor pathways involved in HCC [12–16]. The identification of several cell signaling pathways...
involved in tumor pathogenesis provide an opportunity to identify novel targets that can be utilized for therapeutic development. Targeted therapies act specifically on tumorigenesis regulating components, unlike broad-spectrum, conventional cytotoxic agents. Currently, the only approved drug for advanced HCC is Sorafenib, which partially targets the multi-kinases involved in advanced liver cancer [17,18]. The limitations of existing treatment options has led to a quest for the development of novel targeted therapies against HCC. In the last several years, there has been growing interest in molecular mechanisms playing a critical role in the development of HCC. Numerous signaling pathways have been observed to be dysregulated, either in response to viral infection or by exposure to toxic agents in HCC. Important gains in HCC biology suggest that alterations in multiple molecular signaling pathways such as Receptor tyrosine pathways, phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), Ras mitogen-activated protein kinase (Ras/Raf/MAPK), Wnt/β-catenin, Janus kinase (Jak)-signal transducer activator of transcription factor (Stat) (JAK/STAT), Hedgehog (HH) and Hippo signaling pathway are essential for carcinogenesis. With advances in our understanding of the molecular pathways involved in tumorigenesis, there is a growing interest for the development of novel therapeutics targets against the critical genes and signaling molecules regulating multiple pathways. In this review we have discussed recent advances in molecular mechanisms and the key genes underlying the development of HCC and in the advancement of novel strategies for HCC treatment.

2. Molecular Mechanisms and Targeted Therapies

2.1. The Receptor Tyrosine Kinase Pathways

Receptors that activate multiple downstream signals in the receptor tyrosine kinase pathway include the epidermal growth factor (EGF) receptor, the fibroblast growth factor (FGF) receptor, the hepatocyte growth factor (HGF/c-MET), the stem cell growth factor receptor c-KIT, the platelet-derived growth factor (PDGF) receptor, and the vascular endothelial growth factor (VEGF) receptor. Ligand binding and phosphorylation of these receptors, including the activation of the Grb2/Shc/SOS adapter molecule complex, lead to downstream activation of MAPK and PI3K pathways. Ras/Raf/MEK/extracellular signal regulated kinase (ERK) pathway activation results in the activation of AP-1 transcriptional activators, cJun and cFos, which induce the transcription of genes that drive cell proliferation [19–21]. In HCC, initiation and progression of tumors is significantly affected by many growth factors, including the VEGF, HGF/c-MET, EGFR and IGF receptors (Figure 1).

Figure 1. Schematic representation of major signaling pathways involved in hepatocellular carcinoma.
2.1.1. VEGF Receptor

The liver, being a highly vascular organ, depends on effective angiogenesis for cellular regeneration. Likewise, in HCC, efficient angiogenesis is critical for tumor growth vascular invasion and metastasis [22]. VEGF is a critical angiogenic factor and plays an important regulatory role in HCC. Three main subtypes of VEGF receptor are VEGF 1, 2 and 3. Among the three VEGF subtypes, VEGFR-2 appears to mediate most of the known cellular responses to VEGFs. In spite of the rich vascular supply, liver tumor displays abnormal vasculature such as arteriogenesis and capillarization. There is also abnormal blood flow due to immature liver tumor vessels, which are excessively leaky. This results in severe hypoxia in HCC, which in turn results in the induction of growth factors such as hypoxia-inducible factors 1 and 2 (HIF 1 and 2) and insulin like growth factor 2 (IGF2) [23]. Both HIF1 and IGF2 stimulate expression of VEGF and other growth factors, promoting tumor angiogenesis resulting in tumor progression and metastases. Studies in HCC cell lines and tissues as well as in the serum of patients with HCC have shown increased expression of VEGF and VEGF receptors (including VEGF-1, -2, -3) [24–27]. Increased expression of VEGF mRNA was found in liver tumors in the majority of the HCC patients and is correlated with tumor progression and poor survival [28]. The Hepatitis B x antigen was also associated with the up-regulation of VEGFR-3 [29]. Furthermore, disease recurrence, poor prognosis after resection, vascular invasion, and portal vein embolism are often correlated to high expression of VEGF [28]. Therefore, this suggests a clear regulatory role of VEGF mediated angiogenesis in HCC progression.

2.1.2. EGFR and HGF/c-MET Signals

Mutations in the EGFR signaling pathway appear to be rare in HCC pathogenesis, but it plays a significant role in tumor angiogenesis and proliferation. The IGF signaling pathway is activated by the binding of ligands (IGF-1 and IGF-2) to the membrane bound receptor (IGF-1R) [30]. The IGF signaling pathway regulates several cellular processes, including proliferation, motility and apoptosis inhibition. Binding of the ligand to IGF-1R initiates receptor auto phosphorylation, followed by phosphorylation of intracellular targets (which includes insulin receptor substrates 1–4), which in turn results in the activation of downstream cellular effector factors and eventually activates the PI3K, protein kinase B and RAF/MEK/ERK pathway. The insulin like growth factor (IGF) signaling pathway is frequently dysregulated in HCC. The imbalance of IGF signaling occurs predominantly at the levels of IGF-2 availability. IGF-2 is overexpressed in human HCCs and this excess ligand availability leads to elevated receptor binding and further action on the MAPK and PI3K/AKT/mTOR pathways [31]. Furthermore, overexpression of IGF-2 is correlated with increased cell proliferation in the HCC transgenic mice model [32], whereas IGF-2 ablation reduced cell proliferation and increased apoptosis in SK-hep-1, Hep G2, and Hep 3B HCC cells [33].

HGF is a multifunctional cytokine that has been implicated in the invasion of tumor malignancies [34]. The HGF ligand exerts its effects by binding to the tyrosine kinase receptor c-MET. In addition to tissue regeneration, major functions of c-MET include cell proliferation, migration, survival, branch morphogenesis, and angiogenesis. HGF-induced activation of c-MET leads to self-phosphorylation of the c-MET receptor and further phosphorylation of adaptor proteins (including GRB2) and GAB1 (GRB2-associated -binding protein 1), which then activate downstream effector molecules (including phospholipase C, PI3K, and ERK). Moreover, c-MET dysregulation has been associated with multiple molecular genetic factors and its overexpression is correlated with a reduced five-year survival in HCC patients [35].

Given the contribution of this pathway during liver carcinogenesis, different compounds have been investigated at multiple levels to inhibit receptor tyrosine kinases. This includes inhibitors of the downstream activators like Raf and protein kinase C, as well as antibodies that bind to the receptors blocking ligand-receptor interactions. One such compound is BAY-439006, which inhibit multiple pathway components, Raf kinase and VEGF receptor, and initial clinical studies with this compound have shown partial responses in HCC patients [36]. Other inhibitor compounds relevant to HCC,
for which preclinical studies have been published, include gefitinib [37] EGFR tyrosine kinase inhibitor and FTY720, the PI3K inhibitor, which by downregulating the Rac GTP levels, suppresses the motility of the metastatic H2M HCC cell line [38]. Sunitinib is an oral and multi targeted tyrosine kinase inhibitor targeting VEGFR-1 and -2, PDGF receptor (PDGFR)-α and -β, the stem cell factor receptor c-KIT and others. Preclinical studies in multiple tumor cell lines have shown that the anti-angiogenic effects of sunitinib are mediated through VEGFR and PDGFR-β, however the primary target of sunitinib is likely to be VEGFR-2 [39]. Additional agents involved in inhibiting these signaling pathway components are described in Table 1.

**Table 1.** List of Molecular Targets and potential therapeutic agents used against HCC.

| Targets | Therapeutic Agents | Phase | Reference |
|---------|--------------------|-------|-----------|
| VEGFR, Ras/Raf/MEK/ERK, PDGFR, c-KIT, RET | Sorafenib | 3 | [40,41] |
| VEGFR | Ramucirumab | 3 | [42] |
| VEGFR, PDGFR, FGFR, RET, SCFR | Lenvatinib | 3 | [42] |
| VEGFR, PDGFR, BRAF/FGFR, KIT, RET | Regorafenib | 3 | |
| EGFR/ErbB1/Her1, PI3K/Akt/mTOR | Erlotinib | 3 | [43] |
| PI3K/Akt/mTOR, c-MET | Sirolimus | 3 | [44] |
| VEGFR2, FGFR1 | Brivanib | 3 | [45,46] |
| VEGFR, PDGFR, c-KIT, RET | Sunitinib | 3 | [47] |
| VEGFR, PDGFR | Linifanib | 2 | [48] |
| VEGFR, FGFR, PDGFR, c-KIT | E-7080 | 2 | |
| VEGFR2, FGFR, PDGFR | TSU-68 | 2 | |
| VEGFR2, MET, RET | XL-184 | 2 | |
| VEGFR, PDGFR | Bevacizumab | 2 | [49] |
| VEGFR, PDGFR, c-KIT | Cediranib | 2 | [50] |
| EGFR | Cetuximab | 2 | [42] |
| c-MET | Tivanitib | 2 | [51] |
| VEGFR, PDGFR, FGFR | BIBF-1120 | 2 | [42] |
| VEGFR, EGFR | Vatalanib (PTK787) | 2 | [52] |
| IGE/IGFR | IMC-A12 | 2 | [53] |
| IGE/IGFR | AVE1642 | 1 | [54,55] |
| VEGFR, PDGFR, FGFR-1Raf, RET, c-KIT | BAY73-4506 | 1 | [42] |
| IGF/IGFR | BIIB922 | |
| MEK inhibitor | CI-1040 | | [19] |
| MEK inhibitor | PD 0325901 | | [19] |
| PI3K/Akt/mTOR | AZD8055 | | [56] |
| Wnt-β-catenin | PFK118-310 | | [56] |
| Wnt-β-catenin | PFK115-584 | | |
| Wnt-β-catenin | CGP049090 | | |
| 26S Proteasome | Bortezomib | | [19] |
| STAT3 | CIMO | | [57] |
| Gli1 and Gli3 | Bufalin | | [58] |
| Smo | GDC-0449 | | [59] |
2.2. RAF/MEK/ERK Signaling Pathway

The Raf/MEK/ERK is a ubiquitous signal transduction pathway that regulates crucial cellular processes, including cell proliferation, differentiation, angiogenesis and survival [60]. This pathway is activated by the binding of several growth factors to the receptors, triggering a series of specific phosphorylation events (Figure 1) [61]. This, in turn, activates an adapter molecule complex known as GRB2/SHC/SOS, which triggers the RAF/MEK/ERK pathway. The key molecular signal regulators within the Raf/MEK/ERK pathway is the small GTPase RAS and the serine/threonine kinase RAF. Intermediate signaling is regulated by mitogen/extracellular protein kinases MEK1 and MEK 2, which ultimately led to the phosphorylation of ERK1 and ERK2, the downstream signaling molecules. ERK1/2 regulate cellular activity by acting on a variety of substrates in the cytoplasm and nucleus [62]. The constitutive activation of the Ras/Raf/MAPK pathway was observed in HCC, suggesting its role in tumorigenesis. Furthermore, MEK1/2 phosphorylation was reported to be increased seven-fold in HCC tissues compared to the adjacent benign tissues [63]. In another study, increased expression and activity of signaling intermediates, such as phosphorylated ERK, has been observed in in vivo mouse HCC models and human HCC tissues [64,65]. Additionally, in solid tumors, RAF/MEK/ERK pathway is usually activated by two main mechanisms: (1) oncogenic mutations within the RAS gene, which leads to constitutive CRAF activation [60], and (2) constitutive CRAF activation resulting from a disorder in the overexpression of growth factors and their receptors [60]. Finally, it has been reported that the RAF/MEK/ERK pathway can also be activated by HBV infection in HCC. HBV expresses transcriptional activators by integrating into the host DNA, which eventually activates the RAF/MEK/ERK pathway [66]. Preclinical studies in HCC to target this pathway include oral inhibitors of MEK, a key enzyme in the Ras-Raf-MEK-extracellular signal regulated kinase (ERK) kinase pathway, which is constitutively active in variety of solid tumors. One of such compound is CI-1040, which has shown promising results in phase I, however, in phase II, it has demonstrated insufficient antitumor activity in patients with advanced breast cancer, colon cancer, non-small cell lung cancer and pancreatic cancer. Another compound PD 0325901, a second generation MEK inhibitor, entered clinical development, which has shown enhanced pharmacologic and pharmaceutical properties compared to CI-1040 [19] (Table 1). Erlotinib is a potent and reversible inhibitor of EGFR tyrosine kinase. In an in vitro study, it was shown to inhibit the RAF/MEK/ERK signaling pathway and blocked the signal transducer and activator of transcription-mediated signaling in Huh-7 and HepG2 cells [67]. The phase II study of 38 patients with unresectable or metastatic HCC, treated with Erlotinib, has shown preliminary anti-tumor activity [43]. Overall, the studies suggested that the RAF/MEK/ERK pathway works downstream of various growth factors and hence could be a promising therapeutic target in HCC.

2.3. PI3K/AKT/mTOR Signaling Pathway

In the PI3K/AKT/mTOR signaling pathway, the family of enzymes are activated by binding the of multiple growth factors (IGF and EGF) and cytokines to the receptor [68]. Upon activation, PI3K produces a lipid second messenger phosphoinositol triphosphate (PIP3) and related second messengers, which, in turn, activates AKT/protein kinase B (PKB). Akt is a serine threonine kinase downstream of PI3K. Activated Akt phosphorylates several cytoplasmic proteins and regulates a variety of critical cellular activities. One of the most important downstream effectors of Akt is a mammalian target of rapamycin (mTOR) subfamily of proteins (Figure 1) [69]. Akt activates the small G protein, Ras homolog enriched in brain (Rheb) by phosphorylating the tuberous sclerosis complex (TSC1/TSC2). Rheb, in its GTP-bound state, can activate mTOR. mTOR form a ternary complex to activate its signaling cascade. mTORC1 (mTOR Complex-1) contains mTOR, RAPTOR (Regulatory Associated Protein of mTOR), mammalian LST8/G-protein β-subunit like protein (mLST8/GβL), PRAS40 and DEPTOR. mTORC2 (mTOR Complex-2) consists of mTOR, rapamycin-insensitive companion of mTOR (Rictor), GβL, and mammalian stress activated protein kinase interacting protein 1 (mSIN1). Activated mTOR in turn regulates phosphorylation of the p70-S6 kinase, a serine threonine kinase and translational repressor
protein PHAS-1/4E-BP which regulate cell cycle progression and proliferation. Another critical component of this pathway is Phosphatase and tensin homolog (PTEN). PTEN is a tumor suppressor gene that dephosphorylates PIP3 and blocks Akt activation and serves as a negative regulator of PI3K/AKT/mTOR signaling pathway (Figure 1) [19]. The PI3K/AKT/mTOR signaling pathway is the most critical and hyper activated in about ~50% of HCC. It controls several important cellular processes including cell growth, survival regulation and metabolism in multiple solid tumors [39,56]. It has been reported that anomalies in the PTEN function may lead to hyperactivation of the PI3K/AKT/mTOR pathway in HCC [70]. Importantly, mutation of PTEN gene or reduced PTEN expression is observed in approximately half of all HCC tumors, suggesting that inactivation of PTEN is involved in the pathogenesis of HCC [70,71]. Furthermore, in a transgenic hepatocyte-specific PTEN deficient mouse model, by 80 weeks of age, 66% of PTEN-deficient mice developed HCC [72]. In a microarray study, increased AKT phosphorylation on Ser473 was observed in 23% of HCC patients and was correlated with early HCC recurrence and poor prognosis [73]. mTORC1 and mTORC2 are the two critical components in this signaling pathway. mTORC1 is a downstream signal of AKT, which induce cell cycle progression by activating S6 kinase and regulate protein synthesis. Increased phospho-mTOR expression was detected in 15% of HCCs [74]. Furthermore, increased p70 S6 kinase expression is found in 45% of HCC patients, which is correlated with the mTOR phosphorylation [75]. In a recently reported study, reduced mTOR activity resulted in reduced cell proliferation in HepG2 and Hep3B HCC cell lines and reduced tumor growth in xenograft mouse models [74]. Recently, E2Fs has been shown to play a key role in the development of HCC. E2F family of transcription factors works downstream of cell cycle signaling and plays a crucial role in regulating cellular processes, such as cell proliferation, differentiation, senescence and apoptosis [76]. Studies in human HCC cell lines and transgenic mouse models have demonstrated that E2F1 inhibits c-Myc driven apoptosis via PIK3CA/Akt/mTOR and COX-2 pathways and promotes HCC development [77]. In another study, increased mRNA expression levels of E2Fs were reported in HCC patients and was correlated with poor prognosis and overall survival [78]. Currently, multiple agents targeting PI3K/AKT/mTOR pathways are under investigation for efficacy in treating HCC. Everolimus, mTOR inhibitor, treatment in Hep3B and SNU398 HCC cells has shown significantly reduced proliferative activity [79]. In preclinical HCC models, Everolimus has shown reduced tumor progression and improved survival [80]. In the phase III study, Everolimus was tested in patients with advanced HCC to assess its efficacy. However, no significant difference was observed between the treated and placebo treatment groups [81]. Rapamycin, a macrolide antibiotic with antifungal and immunosuppressive properties, inhibits the mTOR family kinases by binding to cytoplasmic FK506-binding protein-12 (FKBP12) and in complex with FKBP12. Rapamycin treatment in HCC cell lines reduced p70 S6K phosphorylation and significantly inhibited the HCC proliferation, suggesting a strong association between aberrant mTOR activity and HCC progression [75,82]. Taken together, these studies suggest a strong association between PI3K/AKT/mTOR signaling pathway and HCC, and the inhibition of this pathway could be a strong HCC treatment strategy.

2.4. Wnt/β-Catenin Signaling Pathway

In the Wnt/β-catenin signaling pathway, abnormal regulation of the transcription factor, β-catenin (a key component of WNT signaling pathway), play a major role in the development of early events in HCC. The Wnt/β-catenin signaling pathway is composed of Wnts, which are secreted cysteine-rich glycoprotein ligands [83,84]. The binding of these glycoprotein ligands to the members of frizzled family of cell surface receptors activates the receptor-mediated signaling pathway. Out of the nineteen Wnt ligands, binding to ten transmembrane frizzled receptors leads to the activation of either the canonical (β-catenin-dependent) or non-canonical (β-catenin-independent) Wnt pathway. In the absence of Wnt ligands, most β-catenin binds to E-cadherin in adherence junctions at the plasma membrane in most of the cells. Cytosol β-catenin forms complexes with adenomatous polyposis coli (APC) and AXIN1 or AXIN2, mediating sequential phosphorylation and degradation of β-catenin by casein kinase 1 and glycogen synthase kinase 3 β (GSK3β) [85]. In the presence of Wnt ligand, Wnt
ligand binds to the cell surface Frizzled family receptor, resulting in phosphorylation and the inhibition of GSK3β, ensuring an increase in cytosolic β-catenin concentration (Figure 1). This leads to the translocation of β-catenin to the nucleus where it interacts with the TCF and LEF transcription factors and activates the transcription of genes involved in cell proliferation (MYC, MYB, JUN and CYD1) angiogenesis (VEGF, c-MET), anti-apoptosis and the formation of the extracellular matrix [68,83,84]. In approximately 30–40% of human HCC patients, mutation in the β-catenin gene in 12% to 26% of human HCCs and mutations in AXIN 1 or AXIN 2 in 8% to 13% of human HCCs have been reported [86]. Importantly, increased levels of β-catenin in the cytoplasm and nucleus have been reported in approximately 50–70% of tumors in HCC [87], promoting proliferation and suppressing differentiation of tumor cells. Furthermore, studies in β-catenin transgenic mouse models, targeted disruption of the Iqgap2 gene in mice, which is associated with Iqgap1 overexpression and the activation of β-catenin and cyclin D1, lead to the development of HCC. Breeding of Iqgap2-null mice with Iqgap1-null mice resulted in reduced HCC phenotype suggesting that Iqgap2 acts as a tumor suppressor and its loss can lead to β-catenin activation and HCC development [88]. The critical role of Wnt in the regulation of liver regeneration and self-renewal of pluripotent stem cells and progenitor cells hence may be an ideal target for cancer cell therapy. Agents targeting Wnt pathways include small molecule inhibitors that block β-catenin TCF interaction, such as the fungal derivatives PKF115–854 and CPG04909035 or interaction of β-catenin with cAMP response element binding protein (CREB) binding protein (CBP), such as the small molecule ICG-001 [89], and therapeutic monoclonal antibodies against Wnts [90]. Currently several established drugs in clinical use have shown to inhibit Wnt signaling pathway, which includes nonselective cyclooxygenase (COX) inhibitors [19]. In a study, nuclear beta-catenin localisation and beta-catenin/TCF-regulated transcription of target genes was inhibited by nonsteroidal anti-inflammatory drug (NSAID) sulindac treatment, in vitro and in vivo [91]. In another study, treatment of SW948 and SW480 colorectal cancer cells with NSAIDs aspirin and indomethacin has shown reduced signaling activity of β-catenin [92]. The Wnt signaling pathway has a key role to play in HCC and the development of effective therapies would be beneficial to treat HCC.

2.5. JAK/STAT Pathway

The JAK/STAT pathway is activated by multiple cytokines, hormones and growth factors (Figure 1). It is involved in multiple functions such as differentiation, proliferation and apoptosis. In this pathway, the cytokines induce phosphorylation of the JAK family, which consists of four members Jak1, 2, 3 and Tyk2, followed by the activation of six members of the Stat family 1, 2, 3, 4, 5, and 6 [93,94]. Phosphorylation of tyrosine by JAKs results in the activation of this pathway. Activation of the JAK/STAT pathway is tightly controlled by three families of inhibitory proteins, the protein inhibitors of activated Stats (PIAS), the SH2- containing phosphatases (SHP), and the suppressors of cytokine signaling (SOCS) [95,96]. PIAS inhibits STAT-DNA binding and SH-2 is involved in suppression of a variety of cytokine signals. SOCS genes is mediated by STAT activation further inhibiting this pathway by binding to the phosphorylated JAKs and their receptors [97]. This prevents over activation of cytokine stimulated cells. Hence, SOCS functions as a part of negative feedback loop in this pathway. In HCC, a gain in the function mutations in JAKs has been detected to cause JAK/STAT pathway activation [98]. In 9% of patients with Hepatitis B-associated HCC, missense mutations in JAK1 have been identified. In vitro, these mutations increase phosphorylation of JAK1 and STAT3 and enable cytokine-independent growth [99]. STAT activation by JAK stimulation results in the initiation of cell proliferation, migration, differentiation and apoptosis. Importantly, inactivated JAK-binding proteins and activated JAK/STAT pathway have been reported in HCC [100,101]. A significant reduction in liver tumorigenesis, chemically induced by DEN and hepatocyte proliferation, was reported in JNK1 knockout mouse models. It was reported that impaired proliferation was caused by an increased expression of p21, a cell cycle inhibitor. Furthermore, JNK activity ablation using inhibitor D-JNK1 reduced the growth of both xenografted human HCC cells and chemically induced mouse liver cancers [102]. These findings suggest a critical role played by JNK in HCC development and targeting JNK could be an ideal therapeutic approach to
treat HCC. 2-(1-(4-(2-cyanophenyl)1-benzyl-1H-indol-3-yl)-5-(4-methoxy-phenyl)-1-oxa-3-azaspiro(5,5)
undecane (CIMO) has been reported as a potent inhibitor of this pathway in HCC [57]. CIMO
down-regulates constitutively active and inducible upstream kinases (STAT3) and the expression of
target genes in vitro and in vivo and enhances cytotoxicity and deletes the nuclear pool of STAT3 in
HCC (Table 1).

2.6. Hippo Signaling Pathway

Hippo signaling is an evolutionarily conserved pathway that modulates organ size and
development by regulating cell proliferation, survival, differentiation and apoptosis [103]. In mammals,
at the core of the Hippo pathway are serine/threonine kinases, sterile 20-related 1 and 2 kinases
(MST1 and MST2), and large tumor suppressor 1 and 2 kinases (LATS1 and LATS2). MST1/MST2
forms a complex along with Salvador 1 (SAV1) to phosphorylate and activate LATS1/LATS2 [104].
Activated LATS1/LATS2 kinases, in turn, phosphorylate and inhibit the transcription co-activators
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ). Tumor
suppressor neurofibromin 2 (NF2) participates upstream of MST1/MST1 and LATS1/LATS2 kinases to
inhibit YAP and TAZ activity by promoting the activation of the pathway. YAP/TAZ are transcriptional
coactivators and does not comprise DNA binding domain. When LATS1/ LATS2 kinases are inactive,
dephosphorylated YAP/TAZ translocate into the nucleus. In nucleus, YAP/TAZ interact significantly
with TEA DNA-binding proteins (TEAD1–4) transcription factors and forms the YAP/TAZ-TEAD
complex that mediate proliferative and prosurvival genes such as the connective tissue growth
factor (CTGF), cysteine-rich angiogenic inducer 61 (CRY61) and others to promote cell survival,
proliferation and growth [105]. In HCC, dysregulation of the Hippo pathway plays a crucial role
in tumor development. Approximately 50% of human HCC patients show aberrant overexpression
and nuclear localization of YAP [106]. In a study, YAP expression was evaluated in human HCC by
immunochemistry, wherein out of 155 HCC samples tested, 63 samples (54%) showed strong YAP
staining, whereas 95% of normal liver tissue samples showed weak staining, suggesting differences in
YAP protein levels between normal and cancerous tissues. Additionally, analysis of HCC tumorous
tissue showed significantly upregulated YAP protein and mRNA levels, as compared to the adjacent
non-tumor tissue by 62% to 9%, respectively [107,108]. Notably, studies with YAP transgenic mouse
showed YAP overexpression leads to HCC development, suggesting a direct connection between
dysregulation of the Hippo pathway and liver tumorigensis [109]. Overall, these studies suggest that
YAP activation plays a key role in human HCC and dysregulated hippo pathway could be common
mechanism for YAP activation. Given its broad potential therapeutic relevance, there is a significantly
growing interest in targeting the Hippo pathway. Verteporfin, also known as Visudyne, an FDA
approved drug, has been widely reported as a Yap inhibitor [110]. It has been reported to reduce the
expression of mRNAs of known Hippo pathway target genes such as CYR61, CTGF, AXL, and BIRC-5.
Another YAP inhibitor, CA3, has been reported to modulate the YAP/TEAD transcriptional activity
and decrease YAP expression [111]. Studies with Flufenamic acid has shown reduced cell growth,
TEAD reporter activity and various Hippo pathway responsive genes [112]. These studies suggest that
disruption of downstream transcription complexes could be a promising therapeutic approach.

2.7. Ubiquitin-Proteasome Pathway

The ubiquitin-proteasome system (UPS) is involved in cellular protein degradation and is highly
conserved in eukaryotic systems [113]. This pathway plays a vital role in cell homeostasis that
includes receptor signal transduction, cell cycle regulation, endocytosis and apoptosis. Around 80%
ubiquitin labelled protein is degraded by the proteasome in the cytoplasm and nucleus. The rest of the
20%, which is mostly cell surface proteins, are absorbed by endocytosis and degraded in lysosomes.
Ubiquitin-proteasome-mediated protein degradation is accomplished via sequential steps, which
includes ubiquitin-activating enzyme (E1) and multiple ubiquitin-conjugating enzymes (E2s) and
ubiquitin ligases (E3s). ATP-dependent transfer of ubiquitin to an E2 ubiquitin-conjugating enzyme is
mediated by the ubiquitin-activating enzyme E1. Enzyme E2 then transfers the ubiquitin moiety to a downstream E3 ligase, which, in turn, ubiquitinates its specific substrate or substrates. This sequential addition of ubiquitin molecules to the nascent ubiquitin chain results in the formation of a polyubiquitin chain. These polyubiquitinated proteins are determined and degraded by the multisubunit 26S proteasome into peptide fragments and ubiquitin monomers, which are then recycled [19] (Figure 2). A variety of proteins related to cancer are regulated by the ubiquitin-proteasome system, which includes the cell surface tyrosine kinase growth factor receptors (EGFR), the tumor suppressors PTEN, p27, p53, and pRb; transforming growth factor b receptor (TGF-β) and other cell cycle regulators [114]. Recent studies have further elucidated the importance of E3 enzymes as compare to E1 and E2, which has only few reports focused on their roles. E3 ubiquitin ligases expression were found to be overexpressed in multiple human cancers such as lung and breast cancer. Furthermore, E3 ubiquitin ligase overexpression was allied with poor prognosis and reduced patient survival. Importantly, most of the E3 ligases play a key role in carcinogenesis and are required for the maintenance of the cancer cell phenotype. Additionally, in HCC, several cancer-related proteins interacts with enzymes of the ubiquitin-proteasome pathway and has shown to function as tumor suppressors. For example, the E3 ubiquitin ligase murine double minute 2 (MDM2) and BRCA1 both of which regulates p53 levels [115,116], another E3 ligase, Smad ubiquitination regulatory factor-2 (Smurf2), regulates Smad proteins and the TGF-b receptor complex levels [117]. Given the contribution of UPS in HCC, multiple compounds that targets the 26S proteasome complex or individual E3 ligase have been developed. Bortezomib or PS-341 (Velcade), a dipeptide boronic acid analogue, is the first FDA (Food and Drug Administration) approved compound that is a potent, selective and reversible inhibitor of 26S proteasome. Bortezomib have shown to inhibit multiple proteins as it targets the final common effector in the ubiquitin proteasome pathway. Studies with this drug have shown to inhibit tumor growth and induce apoptosis of multiple cancer cell types and hence was approved for the treatment of late-stage multiple myeloma [19].

![Figure 2. The Ubiquitin proteasome pathway.](image-url)
2.8. Hedgehog Signaling Pathway

Currently, the hedgehog (HH) signaling plays a crucial role in tissue pattern, cell differentiation and proliferation. In humans, the HH pathway is activated by three ligands: Sonic Hedgehog (SHH), Indian hedgehog (IHH) and Desert Hedgehog, of which SHH is the most studied [118,119]. HH pathway is composed of the Hedgehog ligand, nuclear transcription factors and two transmembrane protein receptors Patched-1 (Ptch1) and Smoothened (Smo) [56]. SHH ligands binds to the Ptch1 receptors and blocks the inhibition of Ptch-1 on Smo thereby activating the Hh signaling pathway. In the cytoplasm, Smo activates the downstream GLI transcription factors Gli1 and Gli2, known activators, as well as Gli3, a repressor [118], thereby regulate cell growth, differentiation and proliferation. In HCC, HH signaling pathway plays an important role in development and invasion and have been shown to be abnormally activated [120–122]. Additionally, the expression of transmembrane proteins, Ptch1 and Gli1, are detected in 50% of the human HCCs suggesting that this pathway is frequently activated in HCCs. The first study performed by Sicklick et al. in 2006 showed the activation of Hh signaling, as illustrated by the increased expression of Shh, Ptch, Smo and Gli1 in cancer cells, as compared to the respective non-tumors tissues. Additionally, increased levels of Smo was correlated with the increased size of HCC nodules [123]. In another similar study, HH activation was detected by analyzing the expression of Shh, Ptch, Smo and Gli1 in human HCC tumor tissues. Increased expression of these genes were detected in the tumor tissues, as compared to the adjacent normal tissue, further reinforcing the key role of Hh in HCC [124]. Furthermore, studies in liver cancer tissues demonstrated Gli2 gene ablation reduced the expression of c-myc and Bcl-2 and elevated the p27 expression which regulates the cell cycle, reduce proliferation and inhibits the growth of liver cancer cells [125]. Studies in Huh7, Hep3B and HepG2 HCC cells have shown Bufalin (Bu), one of the topoisomerase II inhibitors, influences the Gli1 and Gli3 expression of Hh signaling pathway and inhibits liver cancer cell proliferation, invasion and metastasis [58]. GDC-0449, antagonist of Smo, have shown to reduce the tumor size and significantly reduced cell filtration in HCC bearing mice [59] (Table 1). Considering its involvement in the initiation and development of HCC, Hh targeted therapies could be a promising strategy to combat HCC.

2.9. Liver Cancer Stem Cells

Targeting the tumor microenvironment is another issue. Even though the cells with self-renewing capacity in HCC is well supported, the origin of these cells is not clearly understood. Recently, growing evidence supports the novel notion that tumor initiation can be driven by a subset of cells with stem cell features. These cancer stem cells (CSCs) are responsible for not only tumor initiation, but also for tumor persistence, relapse, metastasis, chemoresistance and radioresistance [42]. This may explain why HCCs are usually resistant to conventional chemotherapies. Additionally, classical therapeutic regimens, as well as new generation therapies (e.g., Sorafenib), predominantly targets proliferating cells, which are unlikely to be CSCs, as evidenced by frequent tumor relapse after therapy [126]. This view of the need for identification and characterization of signaling pathways and biomarkers associated with CSC biology to develop novel molecular cancer therapeutics to treat HCC. Immunohistochemical analysis of 63 HCC tissue specimens revealed CD133, marker for CSCs, to be frequently present in HCC and its expression was found to be increased in 26 specimens (41.3%). Increased levels of CD133 in HCC was correlated with poor survival and high recurrence rate [127]. Another study identifies a novel mechanism in which IL-6 mediated activation of STAT3 signaling resulted in an upregulated expression of CD133 in HCC cells and promotes HCC progression [128]. Further understanding of the molecular pathways involved in the generation of tumorigenic CSCs and the role of CSCs in HCC pathogenesis will provide useful information for developing novel treatments to combat HCC.
2.10. Immune Suppression or Immune escape Mechanisms in HCC

Liver is a lymphoid organ that receives blood from both the systemic circulation and intestine via the hepatic artery and portal vein, respectively. Since the liver is constantly exposed to exogenous antigens it maintains a unique immunological tolerance against invading pathogens. In HCC, tumor microenvironment has a complex interplay of T cells, B-cells, macrophages and hepatic cells to evade immune surveillance by activating multiple cellular signaling cascades. In tumors, the presence of CD8+ T cells is associated with better outcomes, whereas presence of regulatory T cells (Tregs) is correlated with poor prognosis [129]. In a study, Tregs have shown to be involved in the deterioration of anti-tumor effects of T-lymphocytes both in vitro and in vivo [130]. Another study in HCC patients have shown an increased number of circulating Tregs, suggesting a key role in HCC pathogenesis [130]. An alternative mechanism of immune suppression in HCC is via the increase in immunosuppressive cytokines, which includes interleukin-4 (IL-4), IL-5, IL-8, and IL-10, as well as suppression of immune activating cytokines: IL-1, TNF, and interferon gamma [131]. A study with 74 patients with unresectable HCC demonstrated that serum IL-10 concentration is contributing to poor prognosis and low anti-tumor immunity in patients [132]. Recently, modulation of tumor immunity by the programmed cell death-1 (PD-L1/PD-1) immune checkpoint pathway is identified as an alternate mechanism of immune evasion [133]. Immunohistochemical analysis in HCC patients showed increased expression of PD-1 and PD-L1 which promoted CD8+ T-cells apoptosis and contributes to tumor evasion [134]. Recently, blocking of checkpoint molecules that block immune response against tumor cells has being increasingly recognized as an effective therapeutic approach in cancer. In a study from phase I/II trial in advanced HCC patients, anti-PD-1 monoclonal antibody nivolumab has shown antitumor activity [135]. A deeper understanding of immunotherapy and immune tolerance of the liver will be instrumental for designing therapeutic targets to treat HCC.

3. Conclusions and Future Directions

HCC evidently has a complex pathogenesis with many critical signaling pathways being involved in its development. In addition to their independent signaling conduits, there are multiple levels of crosstalk interactions among these signaling pathways to regulate each other. With advances in our understanding of the molecular mechanism of tumorigenesis and in the development of the targeted therapeutics, we are at the beginning of a new era of applications of targeted therapeutics for the treatment of liver cancer. Different strategies that target these pathways showed a varied amount of success in the clinic. In addition, novel strategies have been investigated and raised the potential for more efficient therapies [136–138]. Since HCC is a complex disorder and leads to dysregulation of multiple molecular pathways, it would be great strategy to identify the regulatory proteins that could inhibit two or more major signaling pathways simultaneously. The use of combinatorial trials with two or three drugs may be needed that impact the complex network of signaling pathways to eventually control tumor growth and survival. However, the use of a combination therapy might raise issues such as tolerability and drug-drug interaction, and thus, alternate, targeting molecular agents that control multiple signaling pathways and have multiple modes of action would be better [139]. In addition, targeted drug delivery systems (DDS) have demonstrated a significant potential in HCC treatment by selectively delivering therapeutic drugs into tumor sites. DDS could be utilized to resolve the limitations of conventional chemotherapies. Even though there have been a lot of preclinical studies of DDS, targeted DDS for HCC has yet to be made for clinical use [140]. With further discovery and advances in research on all potential HCC targets, including immunological, molecular and translational, we can generate effective treatment strategies to combat HCC.

Author Contributions: Conceptualization, M.D. and A.S.; Writing—Original Draft Preparation, M.D.; Writing—Review & Editing, M.D. All authors have read and agreed to the published version of the manuscript.

Funding: This research is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DP2DK105565 (AS) of the National Institutes of Health.
Conflicts of Interest: The authors declare no conflict of interest.

References
1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
2. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2014, 136, 359–386. [CrossRef][PubMed]
3. Mittal, S.; El-Serag, H.B. Epidemiology of HCC: Consider the population. J. Clin. Gastroenterol. 2013, 47, S2. [CrossRef] [PubMed]
4. Nordenstedt, H.; White, D.L.; El-Serag, H.B. The changing pattern of epidemiology in hepatocellular carcinoma. Dig. Liver Dis. 2010, 42, S206–S214. [CrossRef]
5. Yang, J.D.; Roberts, L.R. Hepatocellular carcinoma: A global view. Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 448–458. [CrossRef] [PubMed]
6. Okuda, H. Hepatocellular carcinoma development in cirrhosis. Best Pr. Res. Clin. Gastroenterol. 2007, 21, 161–173. [CrossRef] [PubMed]
7. Thomas, M.B.; Abbruzzese, J.L. Opportunities for Targeted Therapies in Hepatocellular Carcinoma. J. Clin. Oncol. 2005, 23, 8093–8108. [CrossRef]
8. Farinati, F.; Sergio, A.; Baldan, A.; Giacomin, A.; Di Nolfo, M.A.; Del Poggio, P.; Benvengu, L.; Rapaccini, G.; Zoli, M.; Borzio, F. Early and very early hepatocellular carcinoma: When and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 2009, 9, 33. [CrossRef]
9. Forner, A.; Bruix, J. Hepatocellular carcinoma—Authors’ reply. Lancet 2012, 380, 470–471. [CrossRef]
10. Dimitroulis, D.; Damaskos, C.; Valsami, S.; Davakis, S.; Garmpis, N.; Spartalis, E.; Athanasiou, A.; Moris, D.; Sakellariou, S.; Kykalos, S. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J. Gastroenterol. 2017, 23, 5282–5294. [CrossRef]
11. Liu, M.; Jiang, L.; Guan, X.-Y. The genetic and epigenetic alterations in human hepatocellular carcinoma: A recent update. Protein Cell 2014, 5, 673–691. [CrossRef] [PubMed]
12. Takahashi, Y. Therapeutic approaches targeting tumor vasculature in gastrointestinal cancers. Front. Biosci. 2011, 3, 541–548. [CrossRef] [PubMed]
13. Chuma, M.; Terashita, K.; Sakamoto, N.; Terashita, K. New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. Hepatol. Res. 2015, 45, E1–E11. [CrossRef] [PubMed]
14. Lee, Y.-H.; Seo, D.; Choi, K.-J.; Andersen, J.B.; Won, M.-A.; Kitade, M.; Gómez-Quiroz, L.E.; Judge, A.D.; Marquardt, J.U.; Raggi, C. Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Res. 2014, 74, 4752–4761. [CrossRef] [PubMed]
15. Dimri, M.; Bilogan, C.; Pierce, L.X.; Naegle, G.; Vasanji, A.; Gibson, I.; McClendon, A.; Tao, K.; Sakaguchi, T.F. Three-dimensional structural analysis reveals a Cdk5-mediated kinase cascade regulating hepatic biliary network branching in zebrafish. Development 2017, 144, 2595–2605. [CrossRef] [PubMed]
16. Elattar, S.; Dimri, M.; Satyanarayana, A. The tumor secretory factor ZAG promotes white adipose tissue browning and energy wasting. FASEB J. 2018, 32, 4727–4743. [CrossRef]
17. Chang, Y.S.; Adnane, J.; Trail, P.A.; Levy, J.; Henderson, A.; Xue, D.; Bortolon, E.; Ichetovkin, M.; Chen, C.; McNabola, A. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharmacol. 2006, 59, 561–574. [CrossRef]
18. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64, 7099–7109. [CrossRef]
19. Roberts, L.R.; Gores, G.J. Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets. Semin. Liver Dis. 2005, 25, 212–225. [CrossRef]
20. Chang, F.; Steelman, L.; Lee, J.; Shelton, J.; Navolanic, P.; Blalock, W.L.; Franklin, R.; McCubrey, J. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Nature Publishing Group: 2003. *Leukemia* **2003**, **17**, 1263–1293. [CrossRef]

21. Yang, S.; Liu, G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. *Oncol. Lett.* **2017**, **13**, 1041–1047. [CrossRef] [PubMed]

22. Semela, D.; Dufour, J.-F. Angiogenesis and hepatocellular carcinoma. *J. Hepatol.* **2004**, **41**, 864–880. [CrossRef] [PubMed]

23. Muto, J.; Shirabe, K.; Sugimachi, K.; Maehara, Y. Review of angiogenesis in hepatocellular carcinoma. *Hepatol. Res.* **2014**, **45**, 1–9. [CrossRef] [PubMed]

24. Shimamura, T.; Saito, S.; Morita, K.; Kitamura, T.; Morimoto, M.; Kiba, T.; Numata, K.; Tanaka, K.; Sekihara, H. Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. *J. Gastroenterol. Hepatol.* **2000**, **15**, 640–646. [CrossRef] [PubMed]

25. Ng, I.O.; Poon, R.T.; Lee, J.M.; Fan, S.T.; Ng, M.; Tso, W.K. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. *Am. J. Clin. Pathol.* **2001**, **116**, 838–845. [CrossRef]

26. Dhar, D.K.; Naora, H.; Yamanoi, A.; Ono, T.; Kohno, H.; Otani, H.; Nagasue, N. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: A comparison with angiopoietin/Tie pathway. *Anticancer. Res.* **2002**, **22**, 379–386.

27. Poon, R.; Ho, J.; Tong, C.; Lau, C.; Ng, I.; Fan, S.T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. *BJS* **2004**, **91**, 1354–1360. [CrossRef]

28. Yamaguchi, R.; Yano, H.; Imura, A.; Ogasawara, S.; Hara, M.; Kojiri, M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. *Hepatology* **1998**, **28**, 68–77. [CrossRef]

29. Lian, Z.; Liu, J.; Wu, M.; Wang, H.Y.; Arbuthnot, P.; Kew, M.; Feitelson, M.A. Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. *Hepatology* **2007**, **45**, 1390–1399. [CrossRef]

30. Alexia, C.; Fallot, G.; Lasfer, M.; Schweizer-Groyer, G.; Groyer, A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. *Biochem. Pharmacol.* **2004**, **68**, 1003–1015. [CrossRef]

31. Cariani, E.; Lasserre, C.; Seurin, D.; Hamelin, B.; Kemeny, F.; Franco, D.; Czech, M.P.; Ullrich, A.; Brechot, C. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. *Cancer Res.* **1988**, **48**, 6844–6849. [PubMed]

32. Schirmacher, P.; Held, W.; Yang, D.; Chisari, F.; Rustum, Y.; Rogler, C. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. *Cancer Res.* **1992**, **52**, 2549–2556. [PubMed]

33. Lund, P.; Schubert, D.; Niketeghad, F.; Schirmacher, P. Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. *Cancer Lett.* **2004**, **206**, 85–96. [CrossRef] [PubMed]

34. Matsumoto, K.; Nakamura, T. Emerging Multipotent Aspects of Hepatocyte Growth Factor. *J. Biochem.* **2004**, **136**, 1–9. [CrossRef]

35. Ueki, T.; Fujimoto, J.; Suzuki, T.; Yamamoto, H.; Okamoto, E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. *Hepatology* **1997**, **25**, 862–866. [CrossRef] [PubMed]

36. Strumberg, D.; Richly, H.; Hilger, R.A.; Schleucher, N.; Korfee, S.; Tewes, M.; Fagih, M.; Brendel, E.; Voliotis, D.; Haase, C.G. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. *J. Clin. Oncol.* **2004**, **22**, 965–972. [CrossRef] [PubMed]

37. Hüpner, M.; Sutter, A.P.; Huether, A.; Schuppan, D.; Zeitz, M.; Scherübl, H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. *J. Hepatol.* **2004**, **41**, 1008–1016. [CrossRef]

38. Lee, T.K.; Man, K.; Ho, J.W.; Wang, X.H.; Poon, R.T.; Sun, C.K.; Ng, K.T.; Ng, I.O.; Xu, R.; Fan, S.T. Significance of the Rac signaling pathway in HCC cell motility: Implications for a new therapeutic target. *Carcinogenesis* **2005**, **26**, 681–687. [CrossRef]
39. Whittaker, S.; Marais, R.; Zhu, A. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. *Oncogene* 2010, 29, 4989–5005. [CrossRef]
40. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.-F.; De Oliveira, A.C.; Santoro, A.; Raoul, J.-L.; Forner, A. Sorafenib in advanced hepatocellular carcinoma. *N. Engl. J. Med.* 2008, 359, 378–390. [CrossRef]
41. Cheng, A.-L.; Kang, Y.-K.; Chen, Z.; Tsao, C.-J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.-S. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol.* 2009, 10, 23–34. [CrossRef]
42. Choi, K.-J.; Baik, I.H.; Ye, S.-K.; Lee, Y.-H. Molecular targeted therapy for hepatocellular carcinoma: Present status and future directions. *Boil. Pharm. Bull.* 2015, 38, 986–991. [CrossRef]
43. Philip, P.A.; Mahoney, M.R.; Allmer, C.; Thomas, J.; Pitot, H.C.; Kim, G.; Donehower, R.C.; Fitch, T.; Picus, J.; Erlichman, C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. *J. Clin. Oncol.* 2005, 23, 6657–6663. [CrossRef] [PubMed]
44. Geissler, E.K.; Schnitzbauer, A.A.; Zülke, C.; Lamby, P.E.; Proneth, A.; Duvoux, C.; Burra, P.; Jauch, K.-W.; Rentsch, M.; Ganten, T.M. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial. *Transplantation* 2016, 100, 116. [CrossRef] [PubMed]
45. Johnson, P.J.; Qin, S.; Park, J.-W.; Poon, R.; Raoul, J.-L.; Philip, P.A.; Hsu, C.-H.; Hu, T.-H.; Heo, J.; Xu, J. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FI study. *J. Clin. Oncol.* 2013, 31, 3517–3524. [CrossRef] [PubMed]
46. Llovet, J.M.; Decaens, T.; Raoul, J.-L.; Boucher, E.; Kudo, M.; Chang, C.; Kang, Y.-K.; Assenat, E.; Lim, H.-Y.; Boige, V. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study. *J. Clin. Oncol.* 2013, 31, 3509–3516. [CrossRef]
47. Cheng, A.-L.; Kang, Y.-K.; Lin, D.-Y.; Park, J.-W.; Poon, R.; Raoul, J.-L.; Philip, P.A.; Hsu, C.-H.; Hu, T.-H.; Heo, J.; Xu, J. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. *J. Clin. Oncol.* 2013, 31, 4067–4075. [CrossRef]
48. Toh, H.C.; Chen, P.J.; Carr, B.I.; Knox, J.J.; Gill, S.; Ansell, P.; McKeegan, E.M.; Dowell, B.; Pedersen, M.; Qin, Q. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. *Cancer* 2012, 119, 380–387. [CrossRef]
49. Siegel, A.B.; Cohen, E.I.; Ocean, A.; Lehrer, D.; Goldenberg, A.; Knox, J.J.; Chen, H.; Clark-Garvey, S.; Weinberg, A.; Mandeli, J. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. *J. Clin. Oncol.* 2008, 26, 2992–2998. [CrossRef]
50. Alberts, S. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)-interim review of toxicity. In Proceedings of the 4th Gastrointestinal Cancer Symposium, Orlando, FL, USA, 19–21 January 2007.
51. Santoro, A.; Rimassa, L.; Borbath, I.; Daniele, B.; Salvagni, S.; Van Laethem, J.L.; Van Vlierberghe, H.; Trojan, J.; Kolligs, F.T.; Weiss, A. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study. *Lancet Oncol.* 2013, 14, 55–63. [CrossRef]
52. Koch, I.; Baron, A.; Roberts, S.; Junker, U.; Palacay-Ramona, M.; Masson, E.; Kay, A.; Wiedenmann, B.; Laurent, D.; Cebon, J. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC). *J. Clin. Oncol.* 2005, 23, 4134. [CrossRef]
53. Abou-Alfa, G.; Gansukh, B.; Chou, J.; Shia, J.; Capanu, M.; Kalin, M.; Chen, H.; Zojwalla, N.; Katz, S.; Reidy, D. Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC). *J. Clin. Oncol.* 2011, 29 (Suppl. 15), 4043. [CrossRef]
54. Wei, Z.; Doria, C.; Liu, Y. Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma. *Clin. Med. Insights Oncol.* 2013, 7, 87–102. [CrossRef]
55. Faivre, S.; Fartoux, L.; Bouattour, M.; Bumsel, F.; Dreyer, C.; Raymond, E.; Rosmorduc, O. A phase I study of AVE1642, a human monoclonal antibody–blocking insulin-like growth factor-1 receptor (IGF-1R), given as a single agent and in combination with sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma (HCC). *J. Clin. Oncol.* 2011, 29 (Suppl. 4), 270. [CrossRef]
56. Chen, C.; Wang, G. Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. *World J. Hepatol.* 2015, 7, 1964–1970. [CrossRef]

57. Mohan, C.D.; Bharathkumar, H.; Bulusu, K.C.; Pandey, V.; Rangappa, S.; Fuchs, J.E.; Shanmugam, M.K.; Dai, X.; Li, F.; Deviassigaman, A. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. *J. Biol. Chem.* 2014, 289, 34296–34307. [CrossRef] [PubMed]

58. Sheng, X.; Sun, X.; Sun, K.; Sui, H.; Qin, J.; Li, Q. Inhibitory effect of bufalin combined with Hedgehog signaling pathway inhibitors on proliferation and invasion and metastasis of liver cancer cells. *Int. J. Oncol.* 2016, 49, 1513–1524. [CrossRef] [PubMed]

59. Jeng, K.-S.; Jeng, C.-J.; Jeng, W.-J.; Sheen, I.-S.; Chang, C.-F.; Hsiau, H.-I.; Hung, Z.-H.; Yu, M.-C.; Chang, F.-Y. Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma. *Am. J. Surg.* 2015, 210, 554–560. [CrossRef] [PubMed]

60. Gollob, J.A.; Wilhelm, S.; Carter, C.; Kelley, S.L. Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. *Semin. Oncol.* 2006, 33, 392–406. [CrossRef] [PubMed]

61. Galuppo, R.; Ramaiyah, D.; Ponte, O.M.; Gedaly, R. Molecular therapies in hepatocellular carcinoma: What can we target? *Dig. Dis. Sci.* 2014, 59, 1688–1697. [CrossRef]

62. Halaschek-Wiener, J.; Wacheck, V.; Kloo, Y.; Jansen, B. Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: Two mechanisms that cooperatively increase p53 function in colon cancer cells. *Cell. Signal.* 2004, 16, 1319–1327. [CrossRef] [PubMed]

63. Huynh, H.; Nguyen, T.T.T.; Chow, P.K.-H.; Tan, P.H.; Soo, K.C.; Tran, E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis. *BMC Gastroenterol.* 2003, 3, 19. [CrossRef] [PubMed]

64. Ito, Y.; Sasaki, Y.; Horimoto, M.; Wada, S.; Tanaka, Y.; Kasahara, A.; Ueki, T.; Hirano, T.; Yamamoto, H.; Fujimoto, J. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. *Hepatology* 1998, 27, 951–958. [CrossRef] [PubMed]

65. Feng, D.Y.; Zheng, H.; Tan, Y.; Cheng, R.X. Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. *World J. Gastroenterol.* 2001, 7, 33–36. [CrossRef] [PubMed]

66. Galuppo, R.; Maynard, E.; Shah, M.; Daily, M.F.; Chen, C.; Spear, B.T.; Gedaly, R. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. *Anticancer Res.* 2014, 34, 1709–1713. [PubMed]

67. Huether, A.; Höpfner, M.; Sutter, A.P.; Baradari, V.; Schüppan, D.; Scherübl, H. Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. *World J. Gastroenterol.* 2006, 12, 5160–5167. [PubMed]

68. Avila, M.A.; Berasain, C.; Sangro, B.; Prieto, J. New therapies for hepatocellular carcinoma. *Hepatology* 2006, 43, 1964–1983. [CrossRef]

69. McCubrey, J.A.; Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Wong, E.W.; Chang, F.; Lehmann, B.; Terrian, D.M.; Milella, M.; Tafuri, A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *BMC Biophys. Acta (BBA) Bioenerg.* 2006, 1773, 1263–1284. [CrossRef]

70. Zhou, Q.; Lui, V.W.; Yeo, W. Erratum: Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. *Future Oncol.* 2011, 7, 1149–1167. [CrossRef]

71. Xu, Z.; Hu, J.; Cao, H.; Pilo, M.G.; Cigliano, A.; Shao, Z.; Xu, M.; Ribback, S.; Dombrowski, F.; Calvisi, D.F. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. *Exp. Mol. Med.* 2018, 50, e417. [CrossRef]

72. Horie, Y.; Suzuki, A.; Kataoka, E.; Sasaki, T.; Hamada, K.; Sasaki, J.; Mizuno, K.; Hasegawa, G.; Kishimoto, H.; Iizuka, M. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. *J. Clin. Investig.* 2004, 113, 1774–1783. [CrossRef] [PubMed]

73. Boyault, S.; Rickman, D.S.; De Reynies, A.; Balabaud, C.; Reboüissou, S.; Jeannot, E.; Héralut, A.; Saric, J.; Belgitti, J.; Franco, D. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. *Hepatology* 2007, 45, 42–52. [CrossRef] [PubMed]

74. Villanueva, A.; Chiang, D.Y.; Newell, P.; Peix, J.; Thung, S.; Alsinet, C.; Tovar, V.; Roayaie, S.; Minguéz, B.; Sole, M. Pivotal role of mTOR signaling in hepatocellular carcinoma. *Gastroenterology* 2008, 135, 1972–1983. [CrossRef] [PubMed]
75. Sahin, F.; Kannangai, R.; Adegbola, O.; Wang, J.; Su, G.; Torbenson, M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res. 2004, 10, 8421–8425. [CrossRef]
76. Dynlacht, B.D. Live or let die: E2F1 and PBK pathways intersect to make life or death decisions. Cancer Cell 2008, 13, 1–2. [CrossRef]
77. Ladu, S.; Calvisi, D.F.; Conner, E.A.; Farina, M.; Factor, V.M.; Thorgeirsson, S.S. E2F1 inhibits c-Myc-driven apoptosis via PI3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 2008, 135, 1322–1332. [CrossRef]
78. Huang, Y.-L.; Ning, G.; Chen, L.-B.; Lian, Y.-F.; Gu, Y.-R.; Wang, J.-L.; Chen, D.-M.; Wei, H.; Huang, Y.-H. Promising diagnostic and prognostic value of E2Fs in human hepatocellular carcinoma. Cancer Manag. Res. 2019, 11, 1725–1740. [CrossRef]
79. Sieghart, W.; Fuereder, T.; Schmid, K.; Cejka, D.; Werzowa, J.; Wrba, F.; Wang, X.; Gruber, D.; Rasoul-Rockenschaub, S.; Peck-Radosavljevic, M. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007, 83, 425–432. [CrossRef]
80. Semela, D.; Piguet, A.-C.; Kolev, M.; Schmitter, K.; Hlushchuk, R.; Djonov, V.; Stoupis, C.; Dufour, J.-F. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Pathol. 2007, 46, 840–848. [CrossRef]
81. Zhu, A.X.; Kudo, M.; Assenat, E.; Cattan, S.; Kang, Y.-K.; Lim, H.Y.; Poon, R.T.; Blanc, J.-F.; Vogel, A.; Chen, C.-L. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA 2014, 312, 57–67. [CrossRef]
82. Grabinski, N.; Ewald, F.; Hofmann, B.T.; Staufer, K.; Schumacher, U.; Nashan, B.; Jücker, M. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol. Cancer 2012, 11, 85. [CrossRef] [PubMed]
83. Apte, U.; Thompson, M.D.; Cui, S.; Liu, B.; Cieply, B.; Monga, S.P. Wnt signaling is Ca2+ dependent in Iqgap2-deficient mice is IQGAP1 dependent. Mol. Cell. Bioi. 2013, 87, 1–24. [CrossRef]
84. Wong, C.M.; Fan, S.T.; Ng, I.O. β-Catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance. Cancer 2001, 92, 136–145. [CrossRef]
85. Schmidt, V.A.; Chiariello, C.S.; Capilla, E.; Miller, F.; Bahou, W.F. Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol. Cell. Biol. 2008, 28, 1489–1502. [CrossRef]
86. Emami, K.H.; Nguyen, C.; Ma, H.; Kim, D.H.; Jeong, K.W.; Eguchi, M.; Moon, R.T.; Teo, J.-L.; Oh, S.W.; Kim, H.Y. A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription. Proc. Natl. Acad. Sci. USA 2004, 101, 12682–12687. [CrossRef]
87. You, L.; He, B.; Xu, Z.; Uematsu, K.; Mazieres, J.; Fuji, N.; Mikami, I.; Reguart, N.; McIntosh, J.K.; Kashani-Sabet, M. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. 2004, 64, 5385–5389. [CrossRef]
88. Boon, E.; Keller, J.; Wormhoudt, T.; Giardiello, F.M.; Offerhaus, G.; Van Der Neut, R.; Pals, S. Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br. J. Cancer 2004, 90, 224–229. [CrossRef]
89. Dihlmann, S.; Klein, S.; Von Knebel Doeberitz, M. Reduction of β-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated β-catenin. Mol. Cancer Ther. 2003, 2, 509–516. [PubMed]
90. Aittomäki, S.; Pesu, M. Therapeutic Targeting of the JAK/STAT Pathway. Basic Clin. Pharmacol. Toxicol. 2013, 114, 18–23. [CrossRef] [PubMed]
91. Rawlings, J.S; Rosler, K.M.; Harrison, D. The JAK/STAT signaling pathway. J. Cell Sci. 2004, 117, 1281–1283. [CrossRef] [PubMed]
95. Wormald, S.; Hilton, D. Inhibitors of Cytokine Signal Transduction. J. Biol. Chem. 2003, 279, 821–824. [CrossRef]

96. Krebs, D.L.; Hilton, D. SOCS Proteins: Negative Regulators of Cytokine Signaling. Stem Cells 2001, 19, 378–387. [CrossRef]

97. Seif, F.; Khoshmirsafo, M.; Aazami, H.; Mohsenzadegan, M.; Sedighi, G.; Bahar, M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun. Signal. 2017, 15, 1–13. [CrossRef]

98. Thomas, S.; Snowden, J.; Zeidler, M.; Danson, S. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer 2015, 113, 365–371. [CrossRef]

99. Kan, Z.; Zheng, H.; Liu, X.; Li, S.; Barber, T.D.; Gong, Z.; Gao, H.; Hao, K.; Willard, M.D.; Xu, J. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013, 23, 1422–1433. [CrossRef]

100. Yasuda, E.; Kumada, T.; Takai, S.; Ishisaki, A.; Noda, T.; Matsushima-Nishiwaki, R.; Yoshimi, N.; Kato, K.; Toyoda, H.; Kaneoka, Y. Attenuated phosphorylation of heat shock protein 27 correlates with tumor progression in patients with hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2005, 337, 337–342. [CrossRef]

101. Calvisi, D.F.; Ladu, S.; Gorden, A.; Conner, E.A.; Lee, J.S.; Factor, V.M.; Thorgeirsson, S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130, 1117–1128. [CrossRef]

102. Hui, L.; Zatloukal, K.; Scheuch, H.; Stepniak, E.; Wagner, E.F. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Investig. 2008, 118, 3943–3953. [CrossRef] [PubMed]

103. Boopathy, G.T.K.; Hong, W. Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis. Front. Cell Dev. Biol. 2019, 7, 49. [CrossRef] [PubMed]

104. Calses, P.C.; Crawford, J.J.; Lill, J.R.; Dey, A. Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities. Trends Cancer 2019, 5, 297–307. [CrossRef] [PubMed]

105. Shi, X.; Zhu, H.-R.; Liu, T.-T.; Shen, X.-Z.; Zhu, J.-M. The Hippo pathway in hepatocellular carcinoma: Non-coding RNAs in action. Cancer Lett. 2017, 400, 175–182. [CrossRef] [PubMed]

106. Zhao, B.; Wei, X.; Li, W.; Udan, R.S.; Yang, Q.; Kim, J.; Xie, J.; Ikenoue, T.; Yu, J.; Li, L. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genome Res. 2007, 21, 2747–2761. [CrossRef] [PubMed]

107. Lam-Himlin, D.M.; Daniels, J.A.; Gayyed, M.F.; Dong, J.; Maitra, A.; Pan, D.; Montgomery, E.A.; Anders, R.A. The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: A novel oncogenic pathway. Int. J. Pancreatol. 2007, 37, 103–109. [CrossRef]

108. Steinhardt, A.A.; Gayyed, M.F.; Klein, A.P.; Dong, J.; Maitra, A.; Pan, D.; Montgomery, E.A.; Anders, R.A. Expression of Yes-associated protein in common solid tumors. Hum. Pathol. 2008, 39, 1582–1589. [CrossRef]

109. Xu, C.; Liu, C.; Huang, W.; Tu, S.; Wan, F. Effect of Mst1 overexpression on the growth of human hepatocellular carcinoma HepG2 cells and the sensitivity to cisplatin in vitro. Acta Biochim. Biophys. Sin. 2013, 45, 268–279. [CrossRef]

110. Brodowska, K.; Al-Moujahed, A.; Marmalidou, A.; zu Horste, M.M.; Cichy, J.; Miller, J.W.; Gragoudas, E.; Vavvas, D.G. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp. Eye Res. 2014, 124, 67–73. [CrossRef]

111. Song, S.; Xie, M.; Scott, A.W.; Jin, J.; Ma, L.; Dong, X.; Skinner, H.D.; Johnson, R.L.; Ding, S.; Ajani, J.A. A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol. Cancer Ther. 2017, 17, 443–454. [CrossRef]

112. Bum-Erdene, K.; Zhou, D.; Gonzalez-Gutierrez, G.; Ghozayel, M.K.; Si, Y.; Xu, D.; Shannon, H.E.; Bailey, B.J.; Corson, T.W.; Pollok, K.E. Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD Yap Protein-Protein Interaction. Cell Chem. Biol. 2019, 26, 378–389.e13. [CrossRef] [PubMed]

113. Dawson, S.P. Hepatocellular carcinoma and the ubiquitin–proteasome system. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2008, 1782, 775–784. [CrossRef] [PubMed]

114. Burger, A.M.; Seth, A.K. The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications. Eur. J. Cancer 2004, 40, 2217–2229. [CrossRef] [PubMed]
115. Yang, Y.; Li, C.-C.H.; Weissman, A.M. Regulating the p53 system through ubiquitination. *Oncogene* **2004**, 23, 2096–2210. [CrossRef]

116. Dong, Y.; Hakimi, M.-A.; Chen, X.; Kumaraswamy, E.; Cooch, N.S.; Godwin, A.K.; Shiekhattar, R. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. *Mol. Cell* **2003**, 12, 1087–1099. [CrossRef]

117. Zhang, Y.; Chang, C.; Gehling, D.J.; Hemmati-Brivanlou, A.; Derynck, R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. *Proc. Natl. Acad. Sci. USA* **2001**, 98, 974–979. [CrossRef]

118. Nybakken, K.; Perrimon, N. Hedgehog signal transduction: Recent findings. *Curr. Opin. Genet. Dev.* **2002**, 12, 503–511. [CrossRef]

119. Della Corte, C.M.; Viscardi, G.; Papaccio, F.; Esposito, G.; Martini, G.; Ciardiello, D.; Martinelli, E.; Ciardiello, F.; Morghillo, F. Implication of the Hedgehog pathway in hepatocellular carcinoma. *World J. Gastroenterol.* **2017**, 23, 4330–4340. [CrossRef]

120. Wang, Y.; Han, C.; Lu, L.; Magliato, S.; Wu, T. Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. *Hepatology* **2013**, 58, 995–1010. [CrossRef]

121. Berman, D.M.; Karhadkar, S.S.; Maitra, A.; De Oca, R.M.; Gerstenblith, M.R.; Briggs, K.; Parker, A.R.; Shimada, Y.; Eschleman, J.R.; Watkins, D.N. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. *Nature* **2003**, 425, 846. [CrossRef]

122. Arzumanyan, A.; Sambandam, V.; Clayton, M.M.; Choi, S.S.; Xie, G.; Diehl, A.M.; Yu, D.-Y.; Feitelson, M.A. Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. *Cancer Res.* **2012**, 72, 5912–5920. [CrossRef] [PubMed]

123. Sicklick, J.K.; Li, Y.-X.; Jayaraman, A.; Kannangai, R.; Qi, Y.; Vivekanandan, P.; Ludlow, J.W.; Owzar, K.; Chen, W.; Torbenson, M.S. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. *Carcinogenesis* **2005**, 27, 748–757. [CrossRef] [PubMed]

124. Huang, S.; He, J.; Zhang, X.; Bian, Y.; Yang, L.; Xie, G.; Zhang, K.; Tang, W.; Stelter, A.A.; Wang, Q. Activation of the Hedgehog pathway in human hepatocellular carcinomas. *Carcinogenesis* **2006**, 27, 1334–1340. [CrossRef] [PubMed]

125. Kim, Y.; Yoon, J.W.; Xiao, X.; Dean, N.M.; Monia, B.P.; Marcusson, E.G. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. *Cancer Res.* **2007**, 67, 3583–3593. [CrossRef] [PubMed]

126. Oishi, N.; Wang, X.W. Novel therapeutic strategies for targeting liver cancer stem cells. *Int. J. Biol. Sci.* **2011**, 7, 517–535. [CrossRef]

127. Song, W.; Li, H.; Tao, K.; Li, R.; Song, Z.; Zhao, Q.; Zhang, F.; Dou, K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. *Int. J. Clin. Pr.* **2008**, 62, 1212–1218. [CrossRef]

128. Won, C.; Kim, B.H.; Yi, E.H.; Choi, K.J.; Kim, E.K.; Jeong, J.M.; Lee, J.H.; Jang, J.J.; Yoon, J.H.; Jeong, W.I. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. *Hepatology* **2015**, 62, 1160–1173. [CrossRef]

129. Ormandy, L.A.; Hillelmann, T.; Wedemeyer, H.; Manns, M.P.; Greten, T.F.; Korangy, F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. *Cancer Res.* **2005**, 65, 2457–2464. [CrossRef]

130. Zhao, H.-Q.; Li, W.-M.; Lu, Z.-Q.; Yao, Y.-M. Roles of Tregs in development of hepatocellular carcinoma: A meta-analysis. *World J. Gastroenterol.* **2014**, 20, 7971–7978. [CrossRef]

131. Budhu, A.; Forgues, M.; Ye, Q.-H.; Jia, H.-L.; He, P.; Zanetti, K.A.; Kammula, U.S.; Chen, Y.; Qin, L.-X.; Tang, Z.-Y. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. *Cancer Cell* **2006**, 10, 99–111. [CrossRef]

132. Hattori, E.; Okumoto, K.; Adachi, T.; Takeda, T.; Ito, J.-I.; Sugahara, K.; Watanabe, H.; Saito, K.; Saito, T.; Togashi, H. Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. *Hepatol. Res.* **2003**, 27, 309–314. [CrossRef] [PubMed]

133. Wu, K.; Kryczek, I.; Chen, L.; Zou, W.; Welling, T.H. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. *Cancer Res.* **2009**, 69, 8067–8075. [CrossRef] [PubMed]

134. Shi, F.; Shi, M.; Zeng, Z.; Qi, R.Z.; Liu, Z.W.; Zhang, J.Y.; Yang, Y.P.; Tien, P.; Wang, F.S. PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. *Int. J. Cancer* **2010**, 128, 887–896. [CrossRef] [PubMed]
135. El-Khoueiry, A.B.; Melero, I.; Crocenzi, T.S.; Welling, T.H.; Yau, T.C.; Yeo, W.; Chopra, A.; Grosso, J.; Lang, L.; Anderson, J. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J. Clin. Oncol. 2015, 33 (Suppl. 18), LBA101. [CrossRef]

136. Dimri, M.; Joshi, J.; Shrivastava, N.; Ghosh, S.; Chakraborti, R.; Indracanti, P.K. Prilocaine hydrochloride protects zebrafish from lethal effects of ionizing radiation: Role of hematopoietic cell expansion. Tokai J. Exp. Clin. Med. 2015, 40, 8–15.

137. Dimri, M.; Joshi, J.; Chakrabarti, R.; Sehgal, N.; Sureshbabu, A.; Prem Kumar, I. Todralazine protects zebrafish from lethal effects of ionizing radiation: Role of hematopoietic cell expansion. Zebrafish 2015, 12, 33–47. [CrossRef]

138. Joshi, J.; Dimri, M.; Ghosh, S.; Shrivastava, N.; Chakraborti, R.; Sehgal, N.; Ray, J.; Kumar, I.P. Ligand and Structure Based Models for the Identification of Beta 2 Adrenergic Receptor Antagonists. Curr. Comput. Drug Des. 2015, 11, 222–236. [CrossRef]

139. Dimri, M.; Humphries, A.; Laknaur, A.; Elattar, S.; Lee, T.J.; Sharma, A.; Kolhe, R.; Ande, S. Nqo1 ablation inhibits activation of the PI 3K/Akt and MAPK/ERK pathways and blocks metabolic adaptation in hepatocellular carcinoma. Hepatology 2019, 71, 549–568. [CrossRef]

140. Zhang, X.; Ng, H.L.H.; Lu, A.; Lin, C.; Zhou, L.; Lin, G.; Zhang, Y.; Yang, Z.; Zhang, H. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future. Nanomed. Nanotechnol. Boil. Med. 2016, 12, 853–869. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).